Soluplus®-Stabilized Cucurbitacin B Nanosuspension Enhances Biopharmaceutical Performance and Attenuates FCA-Induced Rheumatoid Arthritis in Rats
Scientia Pharmaceutica · 03.11.2026 · 94 (4) · 103
DOI: 10.3390/scipharm94040103 ↗Kurz gefasst
Fachartikel in der Zeitschrift Scientia Pharmaceutica, online erschienen am 03.11.2026. Verfasst von Rahul Kumar und 6 weiteren Autor:innen. Die Arbeit nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Cucurbitacin B (CucB) has anti-inflammatory potential, but poor aqueous solubility and permeability limit its oral development. This study developed and evaluated a Soluplus®-stabilized CucB nanosuspension (CucB-NS). The formulation was prepared by antisolvent precipitation, optimized using a Box–Behnken design, and evaluated for physicochemical properties, dissolution, ex vivo permeation, pharmacokinetics, anti-arthritic efficacy, safety, and stability. The optimized formulation had a particle size of 201.12 ± 2.21 nm, polydispersity index of 0.115 ± 0.023, zeta potential of −19.89 ± 1.89 mV, and desirability of 0.981. Compared with pure CucB, it increased saturation solubility from 5.6 ± 1.3 to 18.5 ± 1.5 µg/mL, 24 h dissolution from 29.89 ± 4.32% to 61.93 ± 2.45%, and 16 h permeation from 26.5 ± 3.4% to 48.9 ± 5.8%. Oral administration increased Cmax from 35.55 ± 2.66 to 116.59 ± 5.25 ng/mL and AUC0–∞ from 184.46 ± 10.49 to 1266.79 ± 54.24 ng·h/mL, yielding 686.75 ± 8.01% relative bioavailability without altering Tmax. In FCA-induced arthritis, CucB-NS reduced clinical and synovial inflammatory outcomes and improved joint histology. No overt toxicity was observed, and physical stability was maintained for 3 months at 4 ± 2 °C. CucB-NS improved oral exposure and anti-arthritic activity, supporting further preclinical development.
Zitieren
APA
Kumar, R., Manjunath, K., Kumar, S., Shinde, R., Prakash, S. S., Guha, S., & Kiran, S. (2026). Soluplus®-Stabilized Cucurbitacin B Nanosuspension Enhances Biopharmaceutical Performance and Attenuates FCA-Induced Rheumatoid Arthritis in Rats. Scientia Pharmaceutica, 94(4), 103. https://doi.org/10.3390/scipharm94040103
Vancouver
Kumar R, Manjunath K, Kumar S, Shinde R, Prakash SS, Guha S, et al. Soluplus®-Stabilized Cucurbitacin B Nanosuspension Enhances Biopharmaceutical Performance and Attenuates FCA-Induced Rheumatoid Arthritis in Rats. Scientia Pharmaceutica. 2026;94(4):103. doi:10.3390/scipharm94040103
BibTeX
@article{Kumar2026,
author = {Kumar, Rahul and Manjunath, Kavya and Kumar, Sujeet and Shinde, Rushikesh and Prakash, Sanjana S. and Guha, Sourav and Kiran, Sai},
title = {Soluplus®-Stabilized Cucurbitacin B Nanosuspension Enhances Biopharmaceutical Performance and Attenuates FCA-Induced Rheumatoid Arthritis in Rats},
journal = {Scientia Pharmaceutica},
year = {2026},
volume = {94},
number = {4},
pages = {103},
doi = {10.3390/scipharm94040103}
}
EUVIMED